ClinicalTrials.gg

Program

surabgene lomparvovec

Also written as “Surabgene Lomparvovec (ABBV-RGX-314)” and “Surabgene Lomparvovec”.

In AbbVie’s pipeline, VEGF. Its studies are mostly in Macular Degeneration · Diabetic Retinopathy, led by AbbVie.

Furthest: phase 3, since May 28, 20252 company-led studies, 2 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie22 open or runningphase 3since May 28, 2025May 28, 2025Jun 2028phase 3 · NCT07592273
  • Named in AbbVie’s own pipeline as Surabgene lomparvovec (ABBV-RGX-314), phase 3, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First study: phase 3 study in Neovascular Age-related Macular DegenerationFirst studyNCT07007065 · 561 planned · United States, Austria, Belgium and more
  2. Apr 24, 2026Phase 3 study in Diabetic RetinopathyNCT07592273 · 576 planned · United States, Puerto Rico

Ahead

  1. Jun 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07592273
  2. Mar 2033Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT07007065

TargetBeta

“VEGF”the company's pipeline, read by Claude · source

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
RanibizumabruleNovartisphase 4108
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07592273Diabetic Retinopathy · United States, Puerto Rico3RecruitingJun 2028576
NCT07007065Neovascular Age-related Macular Degeneration · United States, Austria, Belgium and more3RecruitingMar 2033561

How it is read

Names in the registry

  • “Surabgene Lomparvovec (ABBV-RGX-314)”, 1 entry
  • “Surabgene Lomparvovec”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.